Monthly Archives: September 2014

Fayetteville North Carolina Stem Cell Research …

Posted: September 16, 2014 at 10:58 pm

Fayetteville NC Stem Cell Research is a complex and beneficial science using stem cells in a lab environment to better understand how normal human development works, and also to look for and develop new treatments for a wide range of human ailments. Fayetteville North Carolina Stem Cell Research involves two types of stem cells, classified as either embryonic stem cells or adult stem cells, which are used according to the type of Fayetteville NC Stem Cell Research that is desired.

Embryonic stem cells are derived from pre-embryos, called blstocysts, approximately three to five days old. They are created specifically for fertilization treatments in the Fayetteville North Carolina Stem Cell Research lab, will not be used to start a pregnancy, and will be discarded if not used for research. Doctors use in-vitro fertilization to create an embryo in a culture dish, which after three to five days becomes a blstocysts. Fayetteville NC Stem Cell Research lab technicians then extract the inner cell mass from the blstocysts, which is used to derive embryonic stem cells in the Fayetteville North Carolina Stem Cell Research facility.Embryonic stem cells are classified as pluripotent.

This means they can develop into any type of cell in a fully developed human body. It should be noted that embryonic stem cells cant develop into placenta or umbilical cord tissues, but they do appear to be able to develop into any other type of cell in a human body. What is so important about embryonic Fayetteville NC Stem Cell Research is that it enables very flexible research, as the stem cells can be grown into any type of cell needing to be researched, at any time, at the Fayetteville North Carolina Stem Cell Research facility. This makes for more efficient and more productive stem call research, promising a faster path to cures for ailments that devastate humanity. Fayetteville NC Stem Cell Research cannot use adult stem cells to generate just any desired tissues since they are already programmed. They are quite useful nonetheless, and Fayetteville North Carolina Stem Cell Research doctors have identified caches of adult stem cells in several tissues of the human body.

Fayetteville NC Stem Cell Research in general has been able to make some wonderful advancement and create excellent treatments using adult stem cells. But there are limitations to doing Fayetteville North Carolina Stem Cell Research using "only" adult stem cells. Adult stem cells are able to give rise to related kinds of cells in their home tissues, but for example Kidney stem cells cannot generate heart cells, and liver stem cells cannot generate brain cells.

A great deal of Fayetteville NC Stem Cell Research remains to be done, and at this point Fayetteville North Carolina Stem Cell Research doctors have developed a technique for getting an adult stem cell to behave similar to an embryonic stem cell. This specialized Fayetteville NC Stem Cell Research technique creates what are called induced pluripotent stem cells (iPS). They can be produced from adult cells in skin, fatty tissue, and other sources. With this, Fayetteville North Carolina Stem Cell Research remains a promising field. There is of course a great deal more work to do, but Fayetteville NC Stem Cell Research promises to benefit mankind in many profound ways.

More:
Fayetteville North Carolina Stem Cell Research ...

Posted in North Carolina Stem Cells | Comments Off on Fayetteville North Carolina Stem Cell Research …

Startup uses 3D printing tech to create alternative to bone grafts

Posted: September 16, 2014 at 10:56 pm

A Michigan startup is using 3D printing technology to help surgeonsreconstruct skeletal defects helpingsurgeons minimize the need for bonegrafts to fill areas with significant missing bone.

Tissue Regeneration Systemsis developing porous, bioresorbable scaffolding that can replace itself with natural bone, leaving no residual implanted device. Instead of requiring metal plates and screws, the material is computer modeled based on CT scan input so that the implants fit a patients exact needs,CEO Jim Fitzsimmons said.

The companyjust raised $2 millionfrom existing investors, which include Venture Investors, the University of Michigan, the Michigan Economic Development Corporation and Wisconsin Alumni Research Foundation.

Rather than repairing simple fractures, the startups platform is most useful in cases of trauma, cancer where bone tumors are removed cases that require complex skeletal reconstruction.

For these kinds of clinical cases, surgeonshave to remove bone from somewhere else in the body the fibula, the scapula or part of the hip and use that to do the reconstruction, Fitzsimmons said. Our technology lets them do thatwithout the need to remove the bone from somewhere else.

The startups skeletal reconstruction and bone regeneration platform has been licensed from the Universities of Michigan and Wisconsin. It last yearreceived 510(k) approval from the Food and Drug Administration for its product that can repair neurosurgical burr holes.

The companys got a coating technology that helps it integrate the implants with an osteoconductive mineral coating that it says enhances bone regeneration and proliferation into and throughout the porous implant. Orthobiologics and bone-growing stem cells can bind easily to the coating, the company said, which allows for a controlled and sustained biologic release to accelerate new bone formation.

Get our daily newsletter or follow us.

Please enter your email below:

Read the original post:
Startup uses 3D printing tech to create alternative to bone grafts

Posted in Michigan Stem Cells | Comments Off on Startup uses 3D printing tech to create alternative to bone grafts

Turmeric Shows Benefit for 530 Health Conditions And Studied for Alzheimer's, Osteo and Rheumatoid Arthritis …

Posted: September 16, 2014 at 10:56 pm

Studio City, CA 91604 (PRWEB) September 16, 2014

A unique , Enhanced Turmeric+ Formula won an Excellence in Health Product Innovation Award presented at the Emord & Associates 20th Anniversary GALA celebration, Sept. 5th & 6th in Cambridge Maryland.

The award was presented to Christian Wilde honoring his research into the healing properties of turmeric and development of turmeric formulations. http://www.abigon.com/buying_turmeric.html Wilde had previously authored two landmark health books, Hidden Causes of Heart Attack and Stroke, (inflammation, cardiologys new frontier) and Miracle Stem Cell Heart Repair documenting how a patients own stem cells or those of a donor are rejuvenating the hearts of no option heart failure patients. He is the author of the Christian Wilde Stem Cell and Turmeric Research Report. Many notables in the health, journalistic, public policy, medical research and integrated medicine fields were honored before an audience of 300 invited guests. Among those receiving awards were, Dr. Julian Whitaker, Dr. Joseph Mercola, Dr. Steven Sinatra, Dr. Joel Wallach, Dr. Andrew Weil, Mike Adams, Durk Pearson and Sandy Shaw and Sean Hannity. The Christian Wilde Enhanced Turmeric+ Formula contains 7 synergizing ingredients, to learn what makes this formula unique visit http://www.abigon.com/buying_turmeric.html, NOW WELCOMING AFFILIATES. The event theme was, The Sacred Fire of Liberty as introduced by George Washington in his inaugural address of 1789.

Read the original:
Turmeric Shows Benefit for 530 Health Conditions And Studied for Alzheimer's, Osteo and Rheumatoid Arthritis ...

Posted in Maryland Stem Cells | Comments Off on Turmeric Shows Benefit for 530 Health Conditions And Studied for Alzheimer's, Osteo and Rheumatoid Arthritis …

Walk To End Alzheimers

Posted: September 16, 2014 at 10:53 pm

Eight hundred people from around Long Island and out of state braved the 90-degree temperature to walk at the Alzheimers Disease Resource Center 11th annual fundraiser event at the Old Bethpage Village Restoration recently.

The event featured a Coney Island theme, with 90 teams walking the paths around the village. The event raised close to $150,000 and the donations are still being tallied. Executive director Mary Ann Malack-Ragona was pleased with the turnout given the sweltering heat of the day. Malack-Ragona said two grants were recently awarded, with $5,000 to the New York Stem Cell Foundation and $3,000 to Dr. Irving Gomolin, chief division of Geriatric Medicine at Winthrop University Hospital in Mineola.

Many local residents came out in support. Photos by Cynthia Paulis

The Stem Cell Foundation makes stem cells not from embryos, but from skin grafts of people who have Alzheimers disease, said Malack-Ragona. This is ground breaking research. The second grant to Dr. Gomolin is doing a study on how the removal of Namenda from the marketplace, which is set to take place at the end of the year and the use of the substitute, an extended release formulation will impact the blood levels of patients with Alzheimers Disease.

Team leaders were asked to come to the stage to be recognized. Randy Bet from Old Bethpage with her group Team Cousins raised the most money for this event coming in at $10,028.

I am proud to be a part of this organization. I want to thank Mary Ann Ragona for all of the work she is doing to keep the funds we raise here on Long Island, said Bet. She has met so much resistance but keeps going.

My father and my mother-in-law both had Alzheimers, so my two children have Alzheimers on both sides of their family. It is really important for us to find a cure for this disease.

One of the major contributors to the team from Syosset was Robert Rankell who donated $7,500. He was honored with a plaque and was humbled by the award.

This is something near and dear to myself and my family members and I walk to help find a cure.

Old Bethpages Al Sasano was the captain of Team Lucy, which boasted 13 members.

Go here to see the original:
Walk To End Alzheimers

Posted in Connecticut Stem Cells | Comments Off on Walk To End Alzheimers

Novel drug targeting leukemia cells enters clinical trial

Posted: September 16, 2014 at 10:53 pm

PUBLIC RELEASE DATE:

16-Sep-2014

Contact: Scott Lafee slafee@ucsd.edu 619-543-6163 University of California - San Diego @UCSanDiego

Researchers at the University of California, San Diego School of Medicine have launched a phase 1 human clinical trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), the most common form of blood cancer in adults.

The new antibody targets ROR1, a protein used by embryonic cells during early development and exploited by cancer cells to promote tumor growth and metastasis, the latter responsible for 90 percent of all cancer-related deaths.

Because ROR1 is not expressed by normal adult cells, scientists believe it is a biomarker of cancer cells in general and cancer stem cells in particular. Because it appears to drive tumor growth and disease spread, they believe it also presents an excellent target for anti-cancer therapy.

Developed at UC San Diego Moores Cancer Center by Thomas Kipps, MD, PhD, who holds the Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues, the antibody is called cirmtuzumab (also known as UC-961). In previous animal studies, Kipps' team reported that ROR1 is singularly expressed on CLL and also on a variety of different cancers, including cancers of the breast, pancreas, colon, lung and ovary. In mouse models of CLL, ROR1 acts as an accelerant when combined with another oncogene to produce a faster-growing, more aggressive cancer.

Cirmtuzumab was developed under the auspices of the California Institute for Regenerative Medicine's HALT leukemia grant awarded to Dennis Carson, MD, principal investigator, and Catriona Jamieson, MD, PhD, co-principal investigator to develop six distinct therapies against cancer stem cells. Kipps led one of the six projects and generated antibodies against ROR1, leading to the cirmtuzumab trial in patients with CLL.

"The primary goal of this phase I clinical trial is to evaluate whether cirmtuzumab is a safe and well-tolerated cancer stem cell-targeted agent in patients with CLL," said Jamieson, chief of the Division of Regenerative Medicine, associate professor of medicine, director of stem cell research at UC San Diego Moores Cancer Center, deputy director of the Sanford Stem Cell Clinical Center and a principal investigator of the cirmtuzumab clinical trial.

Michael Choi, MD, assistant clinical professor of medicine and co-principal investigator of the clinical trial said, "The trial will involve patients with relapsed or refractory CLL, who will receive an intravenous infusion every 14 days at Moores, followed by regular monitoring and clinic visits to assess efficacy and identify and manage any adverse effects. Initial treatment is planned for two months."

See the article here:
Novel drug targeting leukemia cells enters clinical trial

Posted in California Stem Cells | Comments Off on Novel drug targeting leukemia cells enters clinical trial

Trials and tribulations of stem cell therapy

Posted: September 16, 2014 at 10:45 pm

Stem cells broke into the public consciousness in the early 1990s, but progress has been slow. Photo: Bloomberg

Edgar Irastorza was just 31 when his heart stopped beating in October 2008.

A Miami property manager, break-dancer and former high school wrestler, Irastorza had recently gained weight as his wife's third pregnancy progressed. "I kind of got pregnant, too," he said.

During a workout one day, he felt short of breath and insisted that friends rush him to the hospital. Minutes later, his pulse flatlined.

He survived the heart attack, but the scar tissue that resulted cut his heart's pumping ability by a third. He couldn't pick up his children. He couldn't dance. He fell asleep every night wondering if he would wake up in the morning.

Desperation motivated Irastorza to volunteer for a highly unusual medical research trial: getting stem cells injected directly into his heart.

"I just trusted my doctors and the science behind it, and said, 'This is my only chance,'" he said recently.

Over the past five years, by studying stem cells in lab dishes, test animals and intrepid patients like Irastorza, researchers have brought the vague, grandiose promises of stem cell therapies closer to reality.

Stem cells broke into the public consciousness in the early 1990s, alluring for their potential to help the body beat back diseases of degeneration like Alzheimer's, and to grow new parts to treat conditions like spinal cord injuries.

Progress has been slow. The Michael J. Fox Foundation for Parkinson's Research, an early supporter of stem cell research, pulled its financial backing two years ago, saying that it preferred to invest in research that was closer to providing immediate help for Parkinson's disease patients.

The rest is here:
Trials and tribulations of stem cell therapy

Posted in Stem Cell Therapy | Comments Off on Trials and tribulations of stem cell therapy

Stem Cell Treatment for Multiple Sclerosis – Video

Posted: September 16, 2014 at 10:42 pm


Stem Cell Treatment for Multiple Sclerosis
http://msrelief.com According to Dr. Balshi, multiple sclerosis is not a stem cell disease so the stem cells are not affected by MS. Stem cells can be harvested from the fat, activated with...

By: Choose JOY MS Relief

Follow this link:
Stem Cell Treatment for Multiple Sclerosis - Video

Posted in Stem Cell Videos | Comments Off on Stem Cell Treatment for Multiple Sclerosis – Video

Global Stem Cells Group Signs Consortia Innovas, SA to Exclusive Representative Contract for Chile Territory

Posted: September 16, 2014 at 11:45 am

MIAMI (PRWEB) September 15, 2014

Global Stem Cells Group, Inc. has signed an exclusive representative contract with Consortia Innovas, SA, a Santiago, Chile-based health management, development and biotech company. Founded by entrepreneur Enrique Testart, M.D., Consortia Innovas focuses on helping patients gain access to the latest medical treatments regenerative medicine has to offer.

According to Global Stem Cells Group Founder Benito Novas, Testart searches the globe for innovative stem cell companies that fit in with the Chilean markets, and Global Stem Cells Group turned out to be a perfect fit. Innovas will be in charge of all Global Stem Cells Group divisions and programs in Chile, including patient recruiting through Regenestem, physician training and certification trough Stem Cell Training, and stem cell equipment and disposables sales through Adimarket.

Regenestem, Stem Cell Training and Adimarket are all subsidiaries of the Global Stem Cells Group brand.

Our main objective is to organize Chiles first symposium on Stem Cells and Regenerative Medicine in Santiago in early 2015, Novas says. Our new alliance with Consortia Innovas will allow us to establish our brand as the leader in regenerative medicine therapies in Chile.

The first annual Global Stem Cells Symposium is scheduled to take place in Buenos Aires Oct 2, 2014, to be preceded by an intensive two-day hands-on training course in stem cell harvesting, isolation and applications Sept. 27 and 28 at Santiagos Innovas facilities.

The key to Global Stem Cells Groups strategy to expand into foreign markets by recruiting local representatives and distributors like Consortia Innovas to help manage the companys growth in a specific geographic area. Global Stem Cells group requires any company under consideration for the expansion program to have more than five years experience in the health care industry with at least some experience in the field of regenerative medicine .

In addition, geographic alliances require a commitment to a number of stem cell training courses during a one-year period, certification of physicians, and willingness to organize a large medical meeting or symposium in their territory.

To learn more about the Global Stem Cells Group alliance with Consortia Innovas, SA, visit http://www.stemcellsgroup.com, email bnovas(at)stemcellsgroup(dot)com, or call 305.224.1858.

About Global Stem Cell Group:

Continue reading here:
Global Stem Cells Group Signs Consortia Innovas, SA to Exclusive Representative Contract for Chile Territory

Posted in Stem Cells | Comments Off on Global Stem Cells Group Signs Consortia Innovas, SA to Exclusive Representative Contract for Chile Territory

Re-expression of an embryonic signaling pathway in Melanoma utilizes different receptors

Posted: September 16, 2014 at 11:45 am

PUBLIC RELEASE DATE:

12-Sep-2014

Contact: Peggy Murphy pemurphy@luriechildrens.org 773-755-7485 Children's Memorial Hospital

Metastatic melanoma is a highly aggressive skin cancer whose incidence is on the rise at an alarming rate. Research has revealed that metastatic tumor cells share similar signaling pathways with embryonic stem cells to sustain plasticity and growth. However, major regulators of these pathways are often missing in tumor cells, thus allowing uncontrolled tumor growth and spreading to occur.

During early vertebrate development, Nodal, an embryonic growth factor that governs the growth, pattern and position of tissues, is critical for normal maturation. Nodal plays a significant role in maintaining the pluripotency of embryonic stem cells, meaning the ability of stem cells to differentiate into any of the three germ layers that comprise the body. The recent discovery of Nodal's re-expression in several aggressive and metastatic cancers has highlighted its critical role in self-renewal and maintenance of the stem cell-like characteristics of tumor cells such as melanoma. However, the signaling pathway receptors utilized by melanoma cells to propagate Nodal's effect remain(s) mostly anecdotal and unexplored.

The laboratory of Mary J.C. Hendrix, PhD made the novel discovery that embryonic stem cells and metastatic melanoma cells share a similar repertoire of receptors known as Type I serine/threonine kinase(s), but diverge in their Type II receptor expression. Further testing indicated that metastatic melanoma cells and embryonic stem cells use different receptors for Nodal signal transduction. These findings reveal the divergence in Nodal signaling between embryonic stem cells and metastatic melanoma that can impact new therapeutic strategies targeting the re-emergence of embryonic pathways in cancer.

This work is published in the International Journal of Cancer. Mary J.C. Hendrix, PhD points out: "Nodal-expressing tumor cells don't respond favorably to conventional therapies, supporting the premise that a combinatorial approach to targeting Nodal subpopulations within tumors, along with a front-line therapy, would constitute a more rational approach for treating aggressive cancer". Zhila Khalkhali-Ellis, PhD, senior research scientist in the Hendrix laboratory and the lead author says: "Our discoveries are important for advanced stage aggressive melanoma. Given that limited therapeutic options are currently available for this cancer, we have the opportunity to investigate whether the receptors can be modulated so that the signaling molecule can be neutralized to decrease aggressive behavior." The research was supported by the National Institutes of Health.

###

Zhila Khalkhali-Ellis, PhD is Research Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine; and a member of the Cancer Biology and Epigenomics Program of Stanley Manne Children's Research Institute, affiliated with Ann & Robert H. Lurie Children's Hospital of Chicago.

Mary J.C. Hendrix, PhD is President & Scientific Director of Manne Research Institute; Children's Research Fund Professor; William G. Swartchild, Jr. Distinguished Research Professor at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

See original here:
Re-expression of an embryonic signaling pathway in Melanoma utilizes different receptors

Posted in Stem Cells | Comments Off on Re-expression of an embryonic signaling pathway in Melanoma utilizes different receptors

Six Teams to Compete for New Organ Liver Prize

Posted: September 16, 2014 at 11:45 am

Washington, D.C. (PRWEB) September 16, 2014

New Organ, a collective initiative for regenerative medicine, announced today the initial six teams competing for the New Organ Liver Prize, a global prize competition sponsored by the Methuselah Foundation, a biomedical charity. The prize challenge will award $1,000,000 to the first team that creates a regenerative or bioengineered solution that enables a large animal to live 90 days without native liver function.

Initial teams represent scientists from Harvard Medical School, Massachusetts General Hospital, Northwick Park Institute for Medical Research, University College of London, University of Florida, University of Oxford, University of Pittsburgh, and Yokohama City University. Additional teams are under review and will be announced in the future.

New Organ Founder and Methuselah CEO David Gobel: We are gratified to see the initial interest in the Liver Prize. We are doing this because of the millions who need new organs. Organ disease, and the associated organ shortage, represents one of the greatest medical challenges that can be solved. A scientific foundation has been built over the last 15 years to pursue the vision of organs on demand. Its time for a significant societal commitment to that vision.

The prize teams are led by:

Dr. Tahera Ansari (Team Hepavive): Pursuing the decell-recell approach to bioengineering a liver. Dr. Stephen Badylak (Team Badylak): A pioneer in biologic scaffolds using extracellular matrix. Dr. Eric Lagasse (Team Ectogenesis): Grew mini-livers inside the lymph nodes of mice with liver disease. Dr. Bryon Petersen (Team Petersen): An authority on the role of hepatic stem cells in liver pathology. Dr. Takanori Takebe (Team Organ Creative): Created tiny liver buds that grew and functioned in mice. Dr. Basak Uygun (Team HepaTx): First to report proof-of-principle transplantation of engineered liver grafts.

Representing distinguished leaders within regenerative medicine, the Founding Fellows of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) remarked: We strongly and enthusiastically endorse New Organ. Regenerative medicine has made significant advances in the past 15 years and the New Organ Liver Prize represents a golden opportunity for the next leap forward. The public and the medical community will realize a remarkable clinical benefit with the availability of off the shelf whole livers obviating the need for donor organs, and the medical health care system will simultaneously benefit. We hope this forward-looking effort sets the standard that inspires other initiatives to focus all the resources of regenerative medicine on solving major health care challenges.

About New Organ:

New Organ is a collective initiative tackling organ disease by building a prize portfolio and global alliance of partners committed to advancing breakthroughs in bioengineering, banking, and regenerating vital organs, starting with the liver. It is designed to be a collaborative network of government, industry, and philanthropic organizations working together for the benefit of society. In December 2013, the New Organ Liver Prize was launched at the World Stem Cell Summit with $1 million in initial funding from the Methuselah Foundation. Learn more at http://neworgan.org.

About Methuselah Foundation:

Continued here:
Six Teams to Compete for New Organ Liver Prize

Posted in Regenerative Medicine | Comments Off on Six Teams to Compete for New Organ Liver Prize